NALP4 Antibody Summary
| Immunogen |
Antibody was raised against a 13 amino acid synthetic peptide near the center of human NALP4. The immunogen is located within amino acids 330 – 380 of NALP4.
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
NLRP4
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
||
| Control Peptide |
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for NALP4 Antibody
- Cancer/testis antigen 58
- CLR19.5
- CT58PYRIN and NACHT-containing protein 2
- FLJ32126
- NACHT, leucine rich repeat and PYD containing 4
- NACHT, LRR and PYD domains-containing protein 4
- NALP4NACHT, LRR and PYD containing protein 4
- NLR family, pyrin domain containing 4
- nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domaincontaining 4
- PAN2Ribonuclease inhibitor 2
- PYPAF4PAAD and NACHT-containing protein 2
- RNH2PYRIN-containing APAF1-like protein 4
Background
NALP proteins include the apoptosis regulator APAF1 (apoptotic protease activating factor 1) and mammalian NOD-LRR proteins and are thought to be involved in inflammation and reproduction. NALP4, also known as PYRIN-containing APAF1-like protein 4, has a C-terminal leucine-rich repeat (LRR) region, an N-terminal Pyrin domain (PYD) followed by a NACHT domain, and a NACHT-associated domain. In transfected 293 cells, NALP4 suppressed NF-kappaB induction by TNF-alpha and IL-1beta, suggesting NALP4 operates at a point of convergence in these two signaling pathways. NALP4 also suppressed NF-kappaB induction resulting from overexpression of several adapter proteins and protein kinases involved in these pathways, including TRAF2, TRAF6, RIP, and IRAK2, as well as the IKK-alpha and IKK-beta, suggesting that NALP4 is critical in modulating NF-kappaB activity.
